









Markets
/
Stocks
/
nasdaq-rptx
/

Repare Therapeutics Inc

RPTX



View Detailed Chart

2.140USD

-0.010-0.47%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

91.99MMarket Cap

LossP/E TTM



Repare Therapeutics Inc

2.140

-0.010-0.47%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-0.47%

5 Days

0.00%

1 Month

+1.42%

6 Months

+51.77%

Year to Date

+63.36%

1 Year

+62.12%

View Detailed Chart

TradingKey Stock Score of Repare Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Repare Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 97/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Repare Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

97 / 404

Overall Ranking

213 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.000

Target Price

+39.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Repare Therapeutics Inc Highlights

StrengthsRisks

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.48M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 53.48M.

Fairly Valued

The company’s latest PE is -1.27, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.75M shares, decreasing 25.53% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 724.16K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.68.